People · Operator
Named in public records as an officer, director or promoter · active 2012–2022 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cardurion Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $431.7M | $2.8B | 2021 |
| Rhythm Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $60.5M | $696.2M | 2015 |
| Rhythm Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $60.0M | $765.1M | 2012 |
| Rhythm Holding Company, LLC | — | Pharmaceuticals | Series A | $11.0M | $340.7M | 2013 |
Keith Gottesdiener at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Keith Gottesdiener on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Edward Mathers | 3 | 12 |
| Bart Henderson | 2 | 3 |
| Lou Tartaglia | 2 | 3 |
| Christian De La Tour | 2 | 2 |
| Todd Foley | 1 | 12 |
| Amy Schulman | 1 | 11 |
| Daniel Lynch | 1 | 7 |
| NEIL EXTER | 1 | 5 |
| Steven St. Peter | 1 | 4 |
| Emma Reeve | 1 | 4 |
| Edward T. Mathers | 1 | 3 |
| Vaughn M. Kailian | 1 | 3 |
| Peter Lawrence | 1 | 3 |
| Jonathan T. Silverstein | 1 | 3 |
| Kenneth Novack | 1 | 3 |
| Evan Rachlin | 1 | 3 |
| Adam Koppel | 1 | 3 |
| David P. Meeker, M.D. | 1 | 2 |
| Nicholas Downing | 1 | 2 |
| Jeb Keiper | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.